Dr. Mark L. Hayman specializes in patent counseling, procurement, and licensing for the life sciences industry, and works with companies at all stages to build intellectual property (IP) portfolios that protect foundational technologies and pipeline programs alike. Mark works with emerging life sciences companies to identify important IP generating opportunities, and to design and implement effective patent strategies taking into account the competitive landscape and business environment.
Mark is well versed in building patent portfolios to optimize product exclusivity positions for a wide array of technologies, including protein and peptide therapeutics; metabolic engineering and enzyme engineering; microbiome-related diagnostics and therapeutics; nucleic acid-based therapeutics; diagnostic and prognostic tests, including genetic, gene expression, proteomic and cell-based tests for personalized medicine applications; bioinformatics; nucleic acid sequencing and detection technologies; recombinant protein production; nanoparticle-based drug delivery platforms; and wound care technologies.
Mark co-authored several publications in peer-reviewed journals, including the Journal of Biological Chemistry, Nucleic Acids Research, Infection and Immunity,and Nature Biotechnology. Prior to joining Morgan Lewis, Mark was a partner in the corporate practice group of another international law firm.
State University of New York at Buffalo, 2000, Doctor of Philosophy, Microbiology
State University of New York at Potsdam, 1994, Bachelor of Arts, Biology
University of Pittsburgh School of Law, 2003, Juris Doctor
District of Columbia
United States Patent and Trademark Office
Awards and Affiliations
Recognized, IAM Patent 1000: The World's Leading Patent Professionals (2020, 2021)
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)